Head and Neck Cancer Therapeutics - Global Strategic Business Report

The global market for Head and Neck Cancer Therapeutics was valued at US$2.0 Billion in 2024 and is projected to reach US$2.7 Billion by 2030, growing at a CAGR of 5.7% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Head and Neck Cancer Therapeutics market.

Global Head and Neck Cancer Therapeutics Market - Key Trends and Drivers Summarized

How Are Advances in Head and Neck Cancer Therapeutics Transforming Oncology?

The head and neck cancer therapeutics market has seen remarkable advancements with the development of targeted therapies, immunotherapies, and personalized medicine approaches. Head and neck cancers, including those affecting the oral cavity, pharynx, and larynx, are often linked to factors such as tobacco use, alcohol consumption, and human papillomavirus (HPV) infection. The complexity of these cancers requires a multi-modal treatment approach that includes surgery, radiation, chemotherapy, and emerging biologic therapies. Immunotherapy, particularly immune checkpoint inhibitors, is revolutionizing treatment by enabling the immune system to target and destroy cancer cells, offering new hope for patients with advanced or recurrent cancers.

What Are the Major Segments in the Head and Neck Cancer Therapeutics Market?

Treatment options include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy, with immunotherapy showing promising results in cases where traditional treatments fail. Types of head and neck cancers covered include squamous cell carcinoma, nasopharyngeal carcinoma, and oropharyngeal cancer, among others. End-users include hospitals, oncology clinics, and specialized cancer treatment centers. The rise in early detection through advanced diagnostic tools and personalized treatment plans is improving patient outcomes and expanding the market for head and neck cancer therapies.

How Are Technological Innovations Driving New Therapies for Head and Neck Cancer?

Technological advancements in cancer research are driving innovation in head and neck cancer treatments. The introduction of precision medicine is allowing oncologists to tailor treatments based on the genetic profile of a patient’s tumor, leading to more effective therapies with fewer side effects. Immunotherapy, particularly immune checkpoint inhibitors like pembrolizumab and nivolumab, is at the forefront of therapeutic innovation, offering improved survival rates for patients with advanced cancers. Additionally, advancements in radiation therapy, including intensity-modulated radiation therapy (IMRT), are enabling more precise targeting of tumors, minimizing damage to surrounding healthy tissues. These innovations are transforming the therapeutic landscape for head and neck cancer, providing new avenues for treatment.

What Factors Are Driving the Growth in the Head and Neck Cancer Therapeutics Market?

The growth in the head and neck cancer therapeutics market is driven by several factors, including the increasing prevalence of head and neck cancers globally, rising awareness about early detection, and advancements in cancer treatment modalities. Immunotherapy and targeted therapies are expanding treatment options for patients with difficult-to-treat cancers, contributing to market growth. The growing aging population, which is more susceptible to cancer, is also driving demand for advanced therapeutics. Additionally, increased investment in cancer research, government initiatives to improve access to cancer care, and collaborations between pharmaceutical companies and research institutions are accelerating the development of new and more effective treatments for head and neck cancer.

Report Scope

The report analyzes the Head and Neck Cancer Therapeutics market, presented in terms of units. The analysis covers the key segments and geographic regions outlined below.

Segments: Drug Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors).

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

Market Growth: Understand the significant growth trajectory of the PD Inhibitors segment, which is expected to reach US$2.5 Billion by 2030 with a CAGR of a 7.8%. The EGFR Inhibitors segment is also set to grow at -5.5% CAGR over the analysis period.
Regional Analysis: Gain insights into the U.S. market, valued at $535.1 Million in 2024, and China, forecasted to grow at an impressive 9.7% CAGR to reach $575.4 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

Detailed Market Analysis: Access a thorough analysis of the Global Head and Neck Cancer Therapeutics Market, covering all major geographic regions and market segments.
Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Head and Neck Cancer Therapeutics Market.
Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

How is the Global Head and Neck Cancer Therapeutics Market expected to evolve by 2030?
What are the main drivers and restraints affecting the market?
Which market segments will grow the most over the forecast period?
How will market shares for different regions and segments change by 2030?
Who are the leading players in the market, and what are their prospects?

Report Features:

Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
Company Profiles: Coverage of players such as AB Science SA, AbbVie Inc., Acceleron Pharma, Inc., AstraZeneca Plc., Bayer AG and more.
Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 42 companies featured in this Head and Neck Cancer Therapeutics market report include:

AB Science SA
AbbVie Inc.
Acceleron Pharma, Inc.
AstraZeneca Plc.
Bayer AG
Boston Biomedical, Inc.
Bristol-Myers Squibb
Eli Lilly
F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
Fresenius Medical Care AG & Co. KGaA
Merck
Pfizer, Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Limited

Tariff Impact Analysis: Key Insights for 2025

Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.

The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

What’s Included in This Edition:

Tariff-adjusted market forecasts by region and segment
Analysis of cost and supply chain implications by sourcing and trade exposure
Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

Finalized tariff impacts and new trade agreement effects
Updated projections reflecting global sourcing and cost shifts
Expanded country-specific coverage across the industry

I. METHODOLOGYII. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights
Tariff Impact on Global Supply Chain Patterns
Global Economic Update
Head and Neck Cancer Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Rising Prevalence of Head and Neck Cancers Drives Growth in Therapeutics Market
Technological Advancements in Immunotherapy and Targeted Therapies Propel Market Adoption
Increasing Focus on Personalized Medicine Expands Addressable Market for Cancer Therapeutics
Growing Demand for Minimally Invasive Treatment Options Spurs Innovation in Therapeutics
Rising Healthcare Expenditure and Access to Advanced Cancer Treatments Expand Market Opportunities
Increasing Use of Combination Therapies for Improved Treatment Outcomes Drives Demand
Growing Focus on Early Detection and Diagnosis Strengthens the Market for Therapeutic Interventions
Rising Adoption of Biomarker-Based Therapies and Diagnostics Generates Market Opportunities
Advances in Radiation Therapy and Chemotherapy Techniques Propel Therapeutic Innovation
Rising Awareness About Cancer Prevention and Treatment Expands Patient Access to Therapeutics
Technological Integration of AI and Precision Medicine in Cancer Therapeutics Enhances Market Growth

4. GLOBAL MARKET PERSPECTIVE

Table 1: World Head and Neck Cancer Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
Table 2: World Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
Table 3: World Historic Review for Head and Neck Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 4: World 15-Year Perspective for Head and Neck Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
Table 5: World Recent Past, Current & Future Analysis for PD Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
Table 6: World Historic Review for PD Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 7: World 15-Year Perspective for PD Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
Table 8: World Recent Past, Current & Future Analysis for EGFR Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
Table 9: World Historic Review for EGFR Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 10: World 15-Year Perspective for EGFR Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
Table 11: World Recent Past, Current & Future Analysis for Microtubule Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
Table 12: World Historic Review for Microtubule Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 13: World 15-Year Perspective for Microtubule Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

UNITED STATES

Head and Neck Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
Table 14: USA Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
Table 15: USA Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 16: USA 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030

CANADA

Table 17: Canada Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
Table 18: Canada Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 19: Canada 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030

JAPAN

Head and Neck Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
Table 20: Japan Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
Table 21: Japan Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 22: Japan 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030

CHINA

Head and Neck Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
Table 23: China Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
Table 24: China Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 25: China 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030

EUROPE

Head and Neck Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
Table 26: Europe Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
Table 27: Europe Historic Review for Head and Neck Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 28: Europe 15-Year Perspective for Head and Neck Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
Table 29: Europe Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
Table 30: Europe Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 31: Europe 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030

FRANCE

Head and Neck Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
Table 32: France Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
Table 33: France Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 34: France 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030

GERMANY

Head and Neck Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
Table 35: Germany Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
Table 36: Germany Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 37: Germany 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030

ITALY

Table 38: Italy Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
Table 39: Italy Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 40: Italy 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030

UNITED KINGDOM

Head and Neck Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
Table 41: UK Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
Table 42: UK Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 43: UK 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030

SPAIN

Table 44: Spain Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
Table 45: Spain Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 46: Spain 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030

RUSSIA

Table 47: Russia Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
Table 48: Russia Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 49: Russia 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030

REST OF EUROPE

Table 50: Rest of Europe Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
Table 51: Rest of Europe Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 52: Rest of Europe 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030

ASIA-PACIFIC

Head and Neck Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
Table 53: Asia-Pacific Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
Table 54: Asia-Pacific Historic Review for Head and Neck Cancer Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 55: Asia-Pacific 15-Year Perspective for Head and Neck Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
Table 56: Asia-Pacific Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
Table 57: Asia-Pacific Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 58: Asia-Pacific 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030

AUSTRALIA

Head and Neck Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
Table 59: Australia Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
Table 60: Australia Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 61: Australia 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030

INDIA

Head and Neck Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
Table 62: India Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
Table 63: India Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 64: India 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030

SOUTH KOREA

Table 65: South Korea Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
Table 66: South Korea Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 67: South Korea 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030

REST OF ASIA-PACIFIC

Table 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
Table 69: Rest of Asia-Pacific Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 70: Rest of Asia-Pacific 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030

LATIN AMERICA

Head and Neck Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
Table 71: Latin America Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
Table 72: Latin America Historic Review for Head and Neck Cancer Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 73: Latin America 15-Year Perspective for Head and Neck Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
Table 74: Latin America Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
Table 75: Latin America Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 76: Latin America 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030

ARGENTINA

Table 77: Argentina Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
Table 78: Argentina Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 79: Argentina 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030

BRAZIL

Table 80: Brazil Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
Table 81: Brazil Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 82: Brazil 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030

MEXICO

Table 83: Mexico Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
Table 84: Mexico Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 85: Mexico 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030

REST OF LATIN AMERICA

Table 86: Rest of Latin America Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
Table 87: Rest of Latin America Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 88: Rest of Latin America 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030

MIDDLE EAST

Head and Neck Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
Table 89: Middle East Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
Table 90: Middle East Historic Review for Head and Neck Cancer Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 91: Middle East 15-Year Perspective for Head and Neck Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
Table 92: Middle East Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
Table 93: Middle East Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 94: Middle East 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030

IRAN

Table 95: Iran Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
Table 96: Iran Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 97: Iran 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030

ISRAEL

Table 98: Israel Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
Table 99: Israel Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 100: Israel 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030

SAUDI ARABIA

Table 101: Saudi Arabia Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
Table 102: Saudi Arabia Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 103: Saudi Arabia 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030

UNITED ARAB EMIRATES

Table 104: UAE Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
Table 105: UAE Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 106: UAE 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030

REST OF MIDDLE EAST

Table 107: Rest of Middle East Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
Table 108: Rest of Middle East Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 109: Rest of Middle East 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030

AFRICA

Head and Neck Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
Table 110: Africa Recent Past, Current & Future Analysis for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
Table 111: Africa Historic Review for Head and Neck Cancer Therapeutics by Drug Class - PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
Table 112: Africa 15-Year Perspective for Head and Neck Cancer Therapeutics by Drug Class - Percentage Breakdown of Value Sales for PD Inhibitors, EGFR Inhibitors and Microtubule Inhibitors for the Years 2015, 2025 & 2030

IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

AB Science SA
AbbVie Inc.
Acceleron Pharma, Inc.
AstraZeneca Plc.
Bayer AG
Boston Biomedical, Inc.
Bristol-Myers Squibb
Eli Lilly
F. Hoffmann-La Roche Ltd. (Genentech, Inc.,)
Fresenius Medical Care AG & Co. KGaA
Merck
Pfizer, Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Limited

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5249EUR$5,850USD£4,518GBP
1 - 10 USER LICENSE PDF	The product is a PDF.	This is a 1-10 user license, allowing up to ten users have access to the product.	€9973EUR$11,115USD£8,584GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€15747EUR$17,550USD£13,553GBP

Global Head and Neck Cancer Therapeutics Market - Key Trends and Drivers Summarized

How Are Advances in Head and Neck Cancer Therapeutics Transforming Oncology?

What Are the Major Segments in the Head and Neck Cancer Therapeutics Market?

How Are Technological Innovations Driving New Therapies for Head and Neck Cancer?

What Factors Are Driving the Growth in the Head and Neck Cancer Therapeutics Market?

Report Scope

Key Insights:

Why You Should Buy This Report:

Key Questions Answered:

Report Features:

Some of the 42 companies featured in this Head and Neck Cancer Therapeutics market report include:

Tariff Impact Analysis: Key Insights for 2025

What’s Included in This Edition:

Buyers receive a free July 2025 update with:

Table of Contents

Companies Mentioned (Partial List)

Related Topics

Related Reports

Head and Neck Cancer Therapeutics - A Global Market Overview

Head and Neck Cancer Therapeutics Market Report 2025

PD-1 Resistant Head and Neck Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

Head and Neck Cancer Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

PD-1 Resistant Head and Neck Cancer (HNC) - Market Insight, Epidemiology and Market Forecast - 2034